toripalimab
Loqtorzi (toripalimab) is a PD-1 checkpoint inhibitor from Coherus Oncology for nasopharyngeal carcinoma. With cisplatin and gemcitabine it is a first-line treatment of metastatic or recurrent locally advanced disease, and as monotherapy it treats disease that has progressed after platinum chemotherapy.
This page is based on FDA prescribing information and the EMA medicine record for toripalimab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A tumour raises a molecular white flag that presses the PD-1 brake on attacking T cells, so the immune patrol stands down. Toripalimab covers the brake. The flag no longer works, the T cells stay switched on, and they attack the cancer alongside chemotherapy or on their own after platinum treatment.
In simple terms
T cells are built to destroy abnormal cells, but many cancers protect themselves by displaying ligands PD-L1 and PD-L2 that bind the PD-1 off-switch on T cells. Toripalimab is a humanized antibody given by infusion that binds PD-1 and blocks its engagement by those ligands, preventing the downstream off signal. Freed from suppression, T cells reactivate and attack cancer cells, which is why the drug works in nasopharyngeal carcinoma alone or with chemotherapy.
In depth
Toripalimab is a humanized immunoglobulin G4 monoclonal antibody directed against the negative immunoregulatory receptor programmed cell death 1 (PD-1). Upon administration it binds PD-1 and inhibits the binding of PD-1 to its ligands programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), preventing activation of PD-1 and its downstream signalling pathways. This may restore immune function through activation of T cells and T-cell-mediated immune responses against tumour cells. PD-1 is a transmembrane protein in the immunoglobulin superfamily expressed on activated T cells that negatively regulates T-cell activation and effector function when engaged by its ligands, and it plays an important role in tumour evasion from host immunity.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How toripalimab, a humanized IgG4 anti-PD-1, frees T cells against nasopharyngeal carcinoma
- T cells are built to destroy abnormal cells, but many cancers protect themselves by displaying ligands PD-L1 and PD-L2 that bind the PD-1 off-switch on T cells.
- An inhibitory receptor on activated T cells; when its ligands PD-L1 and PD-L2 engage it, T-cell activation and effector function are suppressed, which tumours exploit to escape immune attack.
- Toripalimab is a humanized immunoglobulin G4 monoclonal antibody directed against the negative immunoregulatory receptor programmed cell death 1 (PD-1).
- With cisplatin and gemcitabine it is a first-line treatment of metastatic or recurrent locally advanced disease, and as monotherapy it treats disease that has progressed after platinum chemotherapy.
Target: Programmed death-1 (PD-1) receptor
An inhibitory receptor on activated T cells; when its ligands PD-L1 and PD-L2 engage it, T-cell activation and effector function are suppressed, which tumours exploit to escape immune attack.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma
- As a single agent, for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy
Approved uses in European Union
EMA- In combination with cisplatin and gemcitabine, for the first-line treatment of adults with recurrent nasopharyngeal carcinoma not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma
- In combination with cisplatin and paclitaxel, for the first-line treatment of adults with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma
Official sources
The statements on this page trace back to these records.
- Loqtorzi (toripalimab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: LOQTORZI (toripalimab) official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: toripalimab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: toripalimab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.